Levomycetin (Tablets, Capsules, Solution, Drops, Powder) Instructions for Use

Instructions
Dosage forms

ATC Code

J01BA01 (Chloramphenicol)

Active Substance

Chloramphenicol (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Antibiotic of the chloramphenicol group

Pharmacotherapeutic Group

Antibiotic

Pharmacological Action

Broad-spectrum antibiotic. The mechanism of antimicrobial action is associated with the disruption of protein synthesis in the microbial cell at the stage of amino acid transfer by tRNA to ribosomes. It has a bacteriostatic effect.

It is active against gram-positive bacteria: Staphylococcus spp., Streptococcus spp.; gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli, Haemophilus influenzae, Salmonella spp., Shigella spp., Klebsiella spp., Serratia spp., Yersinia spp., Proteus spp., Rickettsia spp.; also active against Spirochaetaceae, some large viruses.

Chloramphenicol is active against strains resistant to penicillin, streptomycin, and sulfonamides.

Microbial resistance to chloramphenicol develops relatively slowly.

Pharmacokinetics

After oral administration, it is rapidly and almost completely absorbed from the gastrointestinal tract. Absorption – 90%. Bioavailability – 80%. Plasma protein binding – 50-60%, in premature newborns – 32%. Time to reach C_max after oral administration is 1-3 hours. V_d – 0.6-1 L/kg. Therapeutic concentration in the blood is maintained for 4-5 hours after administration.

It penetrates well into body fluids and tissues. Its highest concentrations are created in the liver and kidneys. Up to 30% of the administered dose is found in bile. C_max in the cerebrospinal fluid (CSF) is determined 4-5 hours after a single oral dose and can reach 21-50% of the C_max in plasma in the absence of meningeal inflammation and 45-89% in the presence of meningeal inflammation.

It crosses the placental barrier; concentrations in the fetal serum can be 30-80% of that in the maternal blood. It is excreted in breast milk. The main amount (90%) is metabolized in the liver. In the intestine, under the influence of intestinal bacteria, it is hydrolyzed to form inactive metabolites.

It is excreted by the kidneys within 24 hours – 90% (via glomerular filtration – 5-10% unchanged, via tubular secretion as inactive metabolites – 80%), through the intestine – 1-3%. T_1/2 in adults is 1.5-3.5 hours, in case of impaired renal function – 3-11 hours. T_1/2 in children from 3 to 16 years old – 3-6.5 hours. It is poorly removed during hemodialysis.

With intravaginal application, it is practically not absorbed and does not have a systemic effect.

Indications

Infectious and inflammatory diseases caused by susceptible microorganisms, including infections of the urinary and biliary tracts.

For external use: in the second phase of the wound process (absence of pus, necrotic tissue), long-term non-healing trophic ulcers, II-III degree burns.

For use in ophthalmology: bacterial eye infections caused by susceptible microorganisms.

For use in gynecology: vaginitis, cervicitis caused by susceptible microorganisms; prevention of purulent-inflammatory diseases in gynecology before invasive procedures (abortion, diathermocoagulation of the cervix, hysterosalpingography, before and after insertion of an intrauterine device).

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
A04.6	Enteritis due to Yersinia enterocolitica
A21	Tularemia
A23	Brucellosis
A28.2	Extraintestinal yersiniosis
A28.8	Other specified bacterial zoonoses, not elsewhere classified
A79	Other rickettsioses
H01.0	Blepharitis
H10.2	Other acute conjunctivitis
H10.4	Chronic conjunctivitis
H10.5	Blepharoconjunctivitis
H15	Diseases of sclera
H16	Keratitis
K65.0	Acute peritonitis (including abscess)
K81.0	Acute cholecystitis
K81.1	Chronic cholecystitis
K83.0	Cholangitis
L01	Impetigo
L02	Cutaneous abscess, furuncle and carbuncle
L03	Cellulitis
L08.0	Pyoderma
L98.4	Chronic skin ulcer, not elsewhere classified
N10	Acute tubulointerstitial nephritis (acute pyelonephritis)
N11	Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30	Cystitis
N34	Urethritis and urethral syndrome
N72	Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
N76	Other inflammatory diseases of vagina and vulva
N77.1	Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere
O08.0	Infection of genital tract and pelvic organs following abortion, ectopic and molar pregnancy
T30	Burns and corrosions of unspecified body region
T79.3	Posttraumatic wound infection, not elsewhere classified
Z29.2	Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes)

ICD-11 code	Indication
1A05	Intestinal infections due to Yersinia enterocolitica
1B70.1	Streptococcal cellulitis of the skin
1B70.2	Staphylococcal cellulitis of the skin
1B70.Z	Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0	Bullous impetigo
1B72.1	Nonbullous impetigo
1B72.Z	Impetigo, unspecified
1B75.0	Furuncle
1B75.1	Carbuncle
1B75.2	Furunculosis
1B75.3	Pyogenic skin abscess
1B94.Z	Tularemia, unspecified
1B95	Brucellosis
1B9A	Extraintestinal yersiniosis
1B9Z	Unspecified zoonotic bacterial diseases
1C3Z	Rickettsioses, unspecified
1F23.10	Candidiasis of vulva and vagina
1F65	Enterobiasis
1H0Z	Unspecified infection
9A01.3	Infectious blepharitis
9A02.Z	Inflammatory disorders of eyelid, unspecified
9A60.4	Blepharoconjunctivitis
9A60.Z	Conjunctivitis, unspecified
9A71	Infectious keratitis
9A7Z	Diseases of the cornea, unspecified
9B5Z	Disorders of sclera, unspecified
DC12.0Z	Acute cholecystitis, unspecified
DC12.1	Chronic cholecystitis
DC13	Cholangitis
DC50.0	Primary peritonitis
DC50.2	Peritoneal abscess
DC50.Z	Peritonitis, unspecified
EA40	Tropical phagedenic ulcer
EB21	Pyoderma gangrenosum
EF60	Ischemic ulceration of the skin
EM0Z	Unspecified skin disorder
GA00	Vulvitis
GA02.Z	Unspecified vaginitis
GA0Z	Inflammatory diseases of female genital tract, unspecified
GB50	Acute tubulo-interstitial nephritis
GB51	Acute pyelonephritis
GB55.Z	Chronic tubulo-interstitial nephritis, unspecified
GB5Z	Renal tubulo-interstitial diseases, unspecified
GC00.Z	Cystitis, unspecified
GC02.Z	Urethritis and urethral syndrome, unspecified
JA05.0	Infection of genital tract or pelvic organs following abortion, ectopic or molar pregnancy
ME60.2	Ulcerative skin lesion of unspecified nature
NE11	Burn of unspecified body region
NF0A.3	Posttraumatic wound infection, not elsewhere classified
QC05.Y	Other specified prophylactic measures
1A94.0	Genital or urogenital tract infection caused by Herpes simplex virus
GA41	Ulcerative or erosive diseases of vulva
GA0Z	Inflammatory diseases of female genital tract, unspecified
XA5WW1	Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Solution

For external use, apply to gauze swabs or directly to the affected area. A regular bandage is applied on top, possibly with parchment or compress paper. Dressings are changed depending on the indications every 1-3 days, sometimes every 4-5 days.

Tablets, Capsules

Take orally. Adults – 500 mg 3-4 times/day. Single doses for children under 3 years old – 15 mg/kg, 3-8 years old – 150-200 mg; over 8 years old – 200-400 mg; frequency of application – 3-4 times/day. The course of treatment is 7-10 days.

Drops

For topical use in ophthalmology every 1-4 hours. The treatment regimen is established individually as prescribed by the doctor.

Powder

Individual, depending on the indications, patient’s age, and the dosage form used.

Adverse Reactions

From the hematopoietic system reticulocytopenia, leukopenia, granulocytopenia, thrombocytopenia, erythrocytopenia; rarely – aplastic anemia, agranulocytosis.

From the digestive system nausea, vomiting, diarrhea, flatulence, dysbiosis.

From the nervous system psychomotor disorders, depression, confusion, peripheral neuritis, optic neuritis, visual and auditory hallucinations, decreased visual and hearing acuity, headache.

Allergic reactions skin rash, urticaria, angioedema.

Local reactions irritant effect (with external or topical application).

Other secondary fungal infection.

With intravaginal application allergic reactions, hematopoietic suppression, dyspepsia, dermatitis, suppression of normal microflora, secondary fungal infection, burning sensation during urination or frequent urination, itching, burning pain or hyperemia of the external genital mucosa, burning or irritation of the penis in the sexual partner, vaginal dysbiosis.

Contraindications

Hypersensitivity to chloramphenicol, bone marrow depression, acute intermittent porphyria, glucose-6-phosphate dehydrogenase deficiency, hepatic and/or renal failure, pregnancy, lactation period; for oral administration – children under 3 years of age and with body weight less than 20 kg; for use in gynecology – fungal diseases of the vagina, not used in girls before the onset of sexual activity; for use in ophthalmology – children under 4 weeks of age.

With caution

Children, patients who have previously received treatment with cytotoxic drugs or radiation therapy.

Use in Pregnancy and Lactation

Chloramphenicol is contraindicated for use during pregnancy and during the lactation (breastfeeding) period.

Use in Hepatic Impairment

Contraindicated in severe liver dysfunction.

Use in Renal Impairment

Contraindicated in severe renal impairment.

Pediatric Use

Use with caution in children.

Geriatric Use

Use with caution in elderly patients to avoid exacerbation of chronic diseases.

Special Precautions

Use with caution in patients who have previously received treatment with cytotoxic drugs or radiation therapy.

When taken simultaneously with alcohol, a disulfiram-like reaction may develop (skin hyperemia, tachycardia, nausea, vomiting, reflex cough, convulsions).

During treatment, systematic monitoring of the peripheral blood picture is necessary.

Uncontrolled prescription of chloramphenicol and its use for mild forms of infectious processes, especially in pediatric practice, is unacceptable.

Drug Interactions

With simultaneous use of chloramphenicol with oral hypoglycemic drugs, an enhancement of the hypoglycemic effect is noted due to the suppression of the metabolism of these drugs in the liver and an increase in their plasma concentration.

With simultaneous use with drugs that depress bone marrow hematopoiesis, an enhancement of the inhibitory effect on the bone marrow is noted.

With simultaneous use with erythromycin, clindamycin, lincomycin, a mutual weakening of the effect is noted due to the fact that Chloramphenicol can displace these drugs from the bound state or prevent their binding to the 50S subunit of bacterial ribosomes.

With simultaneous use with penicillins, Chloramphenicol counteracts the manifestation of the bactericidal action of penicillin.

Reduces the antibacterial effect of cephalosporins.

Chloramphenicol suppresses the cytochrome P450 enzyme system, therefore, with simultaneous use with phenobarbital, phenytoin, warfarin, a weakening of the metabolism of these drugs, a slowdown in their excretion, and an increase in their plasma concentration are noted.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Levomycetin solution In ethanol [Vladivostok Pharmaceutical Factory, JSC (Russia)]
Alcohol solution for external use 0.25%: 25 ml or 40 ml fl.

Marketing Authorization Holder

Vladivostok Pharmaceutical Factory, JSC (Russia)

Dosage Form

Levomycetin solution In ethanol

Alcohol solution for external use 0.25%: 25 ml or 40 ml fl.

Dosage Form, Packaging, and Composition

Solution for external use (alcohol) 0.25%	100 ml
Chloramphenicol	250 mg

25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.

Levomycetin solution In ethanol [Vladivostok Pharmaceutical Factory, JSC (Russia)]
Alcohol solution for external use 1%: 25 ml or 40 ml bottle.

Marketing Authorization Holder

Vladivostok Pharmaceutical Factory, JSC (Russia)

Dosage Form

Levomycetin solution In ethanol

Alcohol solution for external use 1%: 25 ml or 40 ml bottle.

Dosage Form, Packaging, and Composition

Solution for external use (alcohol) 1%	100 ml
Chloramphenicol	1 g

25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.

Levomycetin solution In ethanol [Vladivostok Pharmaceutical Factory, JSC (Russia)]
Alcohol solution for external use 3%: 25 ml or 40 ml bottle

Marketing Authorization Holder

Vladivostok Pharmaceutical Factory, JSC (Russia)

Dosage Form

Levomycetin solution In ethanol

Alcohol solution for external use 3%: 25 ml or 40 ml bottle

Dosage Form, Packaging, and Composition

Solution for external use (alcohol) 3%	100 ml
Chloramphenicol	3 g

25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.

Levomycetin solution In ethanol [Vladivostok Pharmaceutical Factory, JSC (Russia)]
Alcohol solution for external use 5%: 25 ml or 40 ml bottle

Marketing Authorization Holder

Vladivostok Pharmaceutical Factory, JSC (Russia)

Dosage Form

Levomycetin solution In ethanol

Alcohol solution for external use 5%: 25 ml or 40 ml bottle

Dosage Form, Packaging, and Composition

Solution for external use (alcohol) 5%	100 ml
Chloramphenicol	5 g

25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.

Levomycetin solution In ethanol [Tver Pharmaceutical Factory, PJSC (Russia)]
Alcohol solution for external use 3%: 25 ml or 40 ml bottle

Marketing Authorization Holder

Tver Pharmaceutical Factory, PJSC (Russia)

Dosage Form

Levomycetin solution In ethanol

Alcohol solution for external use 3%: 25 ml or 40 ml bottle

Dosage Form, Packaging, and Composition

Solution for external use (alcohol) 3%	100 ml
Chloramphenicol	3 g

25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.

Levomycetin solution In ethanol [Tver Pharmaceutical Factory, PJSC (Russia)]
Alcohol solution for external use 5%: 25 ml or 40 ml bottle

Marketing Authorization Holder

Tver Pharmaceutical Factory, PJSC (Russia)

Dosage Form

Levomycetin solution In ethanol

Alcohol solution for external use 5%: 25 ml or 40 ml bottle

Dosage Form, Packaging, and Composition

Solution for external use (alcohol) 5%	100 ml
Chloramphenicol	5 g

25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.

Levomycetin solution In ethanol [Tver Pharmaceutical Factory, PJSC (Russia)]
Alcohol solution for external use 1%: 25 ml or 40 ml bottle.

Marketing Authorization Holder

Tver Pharmaceutical Factory, PJSC (Russia)

Dosage Form

Levomycetin solution In ethanol

Alcohol solution for external use 1%: 25 ml or 40 ml bottle.

Dosage Form, Packaging, and Composition

Solution for external use (alcohol) 1%	100 ml
Chloramphenicol	1 g

25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.

Levomycetin solution In ethanol [Tver Pharmaceutical Factory, PJSC (Russia)]
Alcohol solution for external use 0.25%: 25 ml or 40 ml fl.

Marketing Authorization Holder

Tver Pharmaceutical Factory, PJSC (Russia)

Dosage Form

Levomycetin solution In ethanol

Alcohol solution for external use 0.25%: 25 ml or 40 ml fl.

Dosage Form, Packaging, and Composition

Solution for external use (alcohol) 0.25%	100 ml
Chloramphenicol	250 mg

25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.

Levomycetin Renewal [Obnovlenie Pfc, JSC (Russia)]
Alcohol solution for external use 0.25%: 25 ml bottle or dropper tube
Alcohol solution for external use 1%: 25 ml bottle or dropper tube
Alcohol solution for external use 3%: 25 ml bottle or dropper tube
Solution for external use, alcohol 5%: bottle or dropper tube 25 ml

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Forms

	Levomycetin Renewal	Alcohol solution for external use 0.25%: 25 ml bottle or dropper tube
		Alcohol solution for external use 1%: 25 ml bottle or dropper tube
		Alcohol solution for external use 3%: 25 ml bottle or dropper tube
		Solution for external use, alcohol 5%: bottle or dropper tube 25 ml

Dosage Form, Packaging, and Composition

Solution for external use, alcohol in the form of a transparent, colorless or yellowish liquid, with the smell of alcohol.

	100 ml
Chloramphenicol	0.25 g

Excipients : ethanol (ethyl alcohol) 70% – up to 100 ml.

25 ml – dark glass bottles (1) – cardboard packs.
25 ml – dropper tubes (1) – cardboard packs.

Solution for external use, alcohol in the form of a transparent, colorless or yellowish liquid, with the smell of alcohol.

	100 ml
Chloramphenicol	1 g

Excipients : ethanol (ethyl alcohol) 70% – up to 100 ml.

25 ml – dark glass bottles (1) – cardboard packs.
25 ml – dropper tubes (1) – cardboard packs.

Solution for external use, alcohol in the form of a transparent, colorless or yellowish liquid, with the smell of alcohol.

	100 ml
Chloramphenicol	3 g

Excipients : ethanol (ethyl alcohol) 70% – up to 100 ml.

25 ml – dark glass bottles (1) – cardboard packs.
25 ml – dropper tubes (1) – cardboard packs.

Solution for external use, alcohol in the form of a transparent, colorless or yellowish liquid, with the smell of alcohol.

	100 ml
Chloramphenicol	5 g

Excipients : ethanol (ethyl alcohol) 70% – up to 100 ml.

25 ml – dark glass bottles (1) – cardboard packs.
25 ml – dropper tubes (1) – cardboard packs.

Levomycetin Renewal [Obnovlenie Pfc, JSC (Russia)]
Film-coated tablets 250 mg: 10, 20, 30, or 50 pcs.
Film-coated tablets 500 mg: 10, 20, 30, or 50 pcs.

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Forms

	Levomycetin Renewal	Film-coated tablets 250 mg: 10, 20, 30, or 50 pcs.
		Film-coated tablets 500 mg: 10, 20, 30, or 50 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets blue in color, round, biconvex; the core on the cross-section is white or almost white.

	1 tab.
Chloramphenicol	250 mg

Excipients : microcrystalline cellulose 101, crospovidone, copovidone (Kollidon VA-64), povidone K30, calcium stearate, colloidal silicon dioxide (aerosil).

Shell composition: [polyvinyl alcohol (E1203), titanium dioxide, macrogol (polyethylene glycol), talc, aluminum lacquer based on indigo carmine dye (E132), yellow iron oxide (E172)] or [dry mix for film coating: polyvinyl alcohol (E1203), titanium dioxide, macrogol (polyethylene glycol), talc, aluminum lacquer based on indigo carmine dye (E132), yellow iron oxide (E172)].

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.

Film-coated tablets blue in color, oval, biconvex, with a score; the core on the cross-section is white or almost white.

	1 tab.
Chloramphenicol	500 mg

Excipients : microcrystalline cellulose 101, crospovidone, copovidone (Kollidon VA-64), povidone K30, calcium stearate, colloidal silicon dioxide (aerosil).

Levomycetin Renewal [Obnovlenie Pfc, JSC (Russia)]
Eye drops 0.25%: dropper tube 1 ml or 2 ml 2 or 5 pcs., 1.5 ml 2 pcs., 5 ml or 10 ml 1 pc.

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Form

Levomycetin Renewal

Eye drops 0.25%: dropper tube 1 ml or 2 ml 2 or 5 pcs., 1.5 ml 2 pcs., 5 ml or 10 ml 1 pc.

Dosage Form, Packaging, and Composition

Eye drops in the form of a transparent, colorless or slightly yellowish liquid.

	1 ml
Chloramphenicol	2.5 mg

Powder for solution for intramuscular administration	1 vial
Chloramphenicol sodium succinate	500 mg

Solvent water for injections – 5 ml.

500 mg – vials (1) in a set with solvent (amp.) – cardboard packs.

Levomycetin succinate sodium [Biokhimik, JSC (Russia)]
Powder for solution for intramuscular administration 1 g: fl. 1 pc. with solvent in a set

Marketing Authorization Holder

Biokhimik, JSC (Russia)

Dosage Form

Levomycetin succinate sodium

Powder for solution for intramuscular administration 1 g: fl. 1 pc. with solvent in a set

Dosage Form, Packaging, and Composition

Powder for solution for intramuscular administration	1 vial
Chloramphenicol sodium succinate	1 g

Eye drops in the form of a transparent liquid with a slightly yellowish tint.

	1 ml
Chloramphenicol	2.5 mg

Excipients : boric acid, water for injections.

5 ml – bottles with a dosing nozzle (1) – cardboard packs.
5 ml – dropper bottles (1) – cardboard packs.
10 ml – bottles with a dosing nozzle (1) – cardboard packs.
10 ml – dropper bottles (1) – cardboard packs.

Levomycetin-DIA [Diafarm, JSC (Russia)]
Eye drops 0.25%: dropper bottle 5 ml or 10 ml

Marketing Authorization Holder

Diafarm, JSC (Russia)

Dosage Form

Levomycetin-DIA

Eye drops 0.25%: dropper bottle 5 ml or 10 ml

Dosage Form, Packaging, and Composition

Eye drops 0.25%	1 ml
Chloramphenicol	2.5 mg

Powder for preparation of solution for intramuscular injection	1 fl.
Chloramphenicol	1 g

Vials (10) – cardboard packs.

Levomycetin-LekT [Patent-Pharm, JSC (Russia)]
Capsules 250 mg: 10 or 20 pcs.

Marketing Authorization Holder

Patent-Pharm, JSC (Russia)

Manufactured By

Tyumen Chemical and Pharmaceutical Plant, JSC (Russia)

Dosage Form

Levomycetin-LekT

Capsules 250 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Capsules hard, gelatin No. 0, white in color, filled with granules of white or white with a faint yellowish-greenish tint.

	1 caps.
Chloramphenicol	250 mg

Excipients: potato starch – 34.5 mg, povidone K-30 – 2.9 mg, calcium stearate – 2.6 mg.

Capsule composition titanium dioxide – 2%, gelatin – up to 100%.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.

Levomycetin-LekT [Tyumen Chemical Pharmaceutical Plant, FSUE (Russia)]
Tablets 500 mg: 10, 20, 30, or 50 pcs.

Marketing Authorization Holder

Tyumen Chemical Pharmaceutical Plant, FSUE (Russia)

Dosage Form

Levomycetin-LekT

Tablets 500 mg: 10, 20, 30, or 50 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Chloramphenicol	500 mg

10 pcs. – contour non-cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour non-cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour non-cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour non-cell packs (1).

Levomycetin-UBF [Uralbiopharm, JSC (Russia)]
Tablets 500 mg: 10, 20, 30, or 50 pcs.

Marketing Authorization Holder

Uralbiopharm, JSC (Russia)

Dosage Form

Levomycetin-UBF

Tablets 500 mg: 10, 20, 30, or 50 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Chloramphenicol	500 mg

10 pcs. – contour cell packs (1) – cardboard packs
10 pcs. – contour cell packs (2) – cardboard packs
10 pcs. – contour cell packs (3) – cardboard packs
10 pcs. – contour cell packs (5) – cardboard packs.

Medixlife (Author)

View all posts Profile link